Research press release


Nature Communications

Disease: Predicting the progression of Alzheimer's disease


過去の研究ではアルツハイマー病患者の脳内で鉄の濃度が上昇していることが観察されているが、脳内鉄濃度とアルツハイマー病の臨床転帰との関連を断定するに至っていない。今回、Ashley Bushたちは、302人の脳脊髄液で検出されたフェリチン濃度と7年間のさまざまな転帰との関連性を調べた。この302人全員は、アルツハイマー病神経イメージングイニシアチブ(ADNI)の前向き臨床コホートに含まれている。



Higher levels of ferritin, an iron storage protein, are associated with reduced cognitive performance and can predict whether a patient suffering from mild cognitive impairment will go on to develop Alzheimer’s disease (AD), reports a study published today in Nature Communications.

Elevation of iron levels has previously been seen in the brains of AD patients but a link between brain iron status and clinical outcomes in AD has not been established. Ashley Bush and colleagues examined the association of ferritin levels, detected in the cerebrospinal fluid of 302 people, with various outcomes over seven years. All of these individuals were part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) prospective clinical cohort.

The authors found a negative association between ferritin levels and cognitive performance in cognitively normal participants, participants with mild cognitive impairment, and AD patients. The authors were able to predict the conversion of mild cognitive impairment to AD based on ferritin levels. Ferritin was strongly associated with levels of the AD biomarker apolipoprotein E and was elevated in people carrying the AD risk variant, APOE-ε4.

These studies link the APOE-ε4 variant with brain iron levels and could point to possible mechanisms by which this mutation confers a risk of developing to AD. The study also supports the implementation of therapeutic strategies that lower brain iron to treat AD, but this would need to be explored in future studies.

doi: 10.1038/ncomms7760

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。